

## *Supplemental Materials*

# **Fusion genes in prostate cancer. A comparison in men of African and European descent.**

**Rebecca Morgan<sup>1</sup>, Dulcie Keeley<sup>1</sup>, E. Starr Hazard<sup>2</sup>, Emma H. Allott<sup>3</sup>, Bethany Wolf<sup>4</sup>, Stephen J. Savage<sup>5,6</sup>, Chanita Hughes Halbert<sup>7,8,9,10</sup>, Sebastiano Gattoni-Celli<sup>6,11</sup> and Gary Hardiman<sup>1,4, 12\*</sup>**

<sup>1</sup> Faculty of Medicine, Health and Life Sciences, School of Biological Sciences & Institute for Global Food Security (IGFS) Queen's University Belfast (QUB), NI, UK; rmorgan21@qub.ac.uk, dkeely02@qub.ac.uk, g.hardiman@qub.ac.uk

<sup>2</sup> Academic Affairs Faculty, Medical University of South Carolina (MUSC), Charleston, SC 29425 hazardes3@gmail.com

<sup>3</sup> Patrick G. Johnston Centre for Cancer Research, QUB, Belfast, Northern Ireland, UK E.Allott@qub.ac.uk

<sup>4</sup> Department of Public Health Sciences, MUSC

<sup>5</sup> Department of Urology, MUSC, Charleston, SC 29425 savages@musc.edu

<sup>6</sup> Ralph H. Johnson VA Medical Center, Charleston, SC USA

<sup>7</sup> Hollings Cancer Center, MUSC, Charleston, SC 29425 hughesha@musc.edu

<sup>8</sup> Department of Psychiatry & Behavioral Sciences, MUSC, Charleston, SC 29425

<sup>9</sup> Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA 90032

<sup>10</sup> Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90033 hughesha@usc.edu

<sup>11</sup> Department of Radiation Oncology, MUSC, Charleston, SC 29425 Sebastiano.Gattoni-Celli@bms.com

<sup>12</sup> Department of Medicine, MUSC, Charleston, SC 29425

\*Correspondence: (GH) G.Hardiman@qub.ac.uk

## **Figure Legends**

### **Figure S1**

Overview of fusion NAIP:OCLN for African American patient 22.

### **Figure S2**

Overview of fusion NAIP:OCLN for African American patient 24.

### **Figure S3**

Overview of fusion NAIP:OCLN for European American patient 15.

### **Figure S4**

Overview of fusion PDE1C:DNAJC6 for African American patient 24.

### **Figure S5**

Overview of fusion KANSL1:ARL17B for European American patient 6.

### **Figure S6**

Overview of fusion KANSL1:ARL17B for European American patient 15.

### **Figure S7**

Overview of fusion FOXP2:CREM for European American patient 1.

### **Figure S8**

Overview of fusion AHSA1:DLG3 for European American patient 15.

## **Tables**

### **Table S1**

Patients IDs, demographic, and clinical information.

### **Table S2**

Summary of model cell lines.

### **Table S3**

Predicted fusions detected by STAR-Fusion, FusionCatcher and JAFFA using model cell lines.

### **Table S4**

Unfiltered fusions detected by each of the four programs, STAR-Fusion, FusionCatcher, JAFFA and ChimeraScan respectively.

### **Table S5**

Summary of predicted fusion genes.

### **Table S6**


Racial differences in predicted fusion genes in African American and European American men.

### **Table S7**

Shared fusions across EA patients using the fusion prediction tools.


### **Table S8**

Shared fusions across AA patients using the fusion prediction tool.




**Figure S1**

Overview of fusion NAIP:OCLN for African American patient 22.




**Figure S2**

Overview of fusion NAIP:OCLN for African American patient 24.




**Figure S3**

Overview of fusion *NAIP*:*OCLN* for European American patient 15.




**Figure S4**

Overview of fusion PDE1C:DNAJC6 for African American patient 24.




**Figure S5**

Overview of fusion KANSL1:ARL17B for European American patient 6.




**Figure S6**

Overview of fusion KANSL1:ARL17B for European American patient 15.



**Figure S7**

Overview of fusion FOXP2:CREM for European American patient 1.



**Figure S8**

Overview of fusion AHSA1:DLG3 for European American patient 15.